Conrad Wüller

Conrad Wüller is currently the Senior Director of Strategy & Operations at ARTBIO, where they focus on developing a new class of alpha radioligand therapies to enhance patient outcomes. They previously served as Head of Medical Strategy for Radioligand Therapy at Novartis and held various roles at leading consulting firms such as McKinsey & Company and Oliver Wyman. Conrad studied business administration at multiple institutions, including Universität Mannheim, the Stockholm School of Economics, and CEMS, earning both a Bachelor of Science and a Master of Science. Born and raised in Germany, they are also an adventurous backpacker and language enthusiast.